- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- IAF: 10 U.S. states will see highest diabetes prevalence, cost
- Leading retailers, suppliers gather in NYC for 14th annual Industry Issues Summit
- Novo Nordisk wins 2010 Good Design Award for NovoPen Echo
- Novo Nordisk develops Cornerstones4Care as diabetes resource
BAGSVÆRD, Denmark — Novo Nordisk is investing 1 billion Danish kroner ($193.9 million) into two new office buildings in Bagsværd, Denmark.
The drug maker said the new premises will house Novo Nordisk’s top management, 1,100 administrative employees and a number of shared facilities.
“Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s,” Novo Nordisk president and CEO Lars Rebien Sørensen said. “The new buildings will give our employees the best conditions for interacting across functional divides and with our colleagues abroad.”